1 134

Cited 20 times in

Quality of Life in the Trastuzumab for Gastric Cancer Trial

DC FieldValueLanguage
dc.contributor.author정현철-
dc.date.accessioned2015-01-06T17:08:07Z-
dc.date.available2015-01-06T17:08:07Z-
dc.date.issued2014-
dc.identifier.issn1083-7159-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99404-
dc.description.abstractBACKGROUND: The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial. PATIENTS AND METHODS: Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQ-STO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. RESULTS: Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. CONCLUSION: Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.-
dc.description.statementOfResponsibilityopen-
dc.format.extent712~719-
dc.relation.isPartOfOncologist-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntibodies, Monoclonal, Humanized/administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCapecitabine-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHCisplatin/adverse effects-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/adverse effects-
dc.subject.MESHDeoxycytidine/analogs & derivatives-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHFluorouracil/adverse effects-
dc.subject.MESHFluorouracil/analogs & derivatives-
dc.subject.MESHHumans-
dc.subject.MESHQuality of Life-
dc.subject.MESHReceptor, ErbB-2/metabolism-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/enzymology-
dc.subject.MESHSurveys and Questionnaires-
dc.subject.MESHTrastuzumab-
dc.titleQuality of Life in the Trastuzumab for Gastric Cancer Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorTaroh Satoha-
dc.contributor.googleauthorYung-Jue Bangb-
dc.contributor.googleauthorEvgeny A. Gotovkinc-
dc.contributor.googleauthorYasuo Hamamotod-
dc.contributor.googleauthorYoon-Koo Kange-
dc.contributor.googleauthorVladimir M. Moiseyenkof-
dc.contributor.googleauthorAtsushi Ohtsug-
dc.contributor.googleauthorEric Van Cutsemh-
dc.contributor.googleauthorNedal Al-Sakaffi-
dc.contributor.googleauthorAlexa Urspruchi-
dc.contributor.googleauthorJulie Hillj-
dc.contributor.googleauthorHarald A. Weberi-
dc.contributor.googleauthorHyun-Cheol Chung-
dc.identifier.doi10.1634/theoncologist.2014-0058-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ02415-
dc.identifier.pmid24951609-
dc.identifier.urlhttp://theoncologist.alphamedpress.org/content/19/7/712-
dc.subject.keywordChemotherapy-
dc.subject.keywordGastric cancer-
dc.subject.keywordHER2-
dc.subject.keywordQuality of life-
dc.subject.keywordTrastuzumab-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.rights.accessRightsfree-
dc.citation.volume19-
dc.citation.number7-
dc.citation.startPage712-
dc.citation.endPage719-
dc.identifier.bibliographicCitationOncologist, Vol.19(7) : 712-719, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.